Home / Business and Economy / Medtronic Buys CathWorks for $585M Heart Tech Boost
Medtronic Buys CathWorks for $585M Heart Tech Boost
3 Feb
Summary
- Medtronic is acquiring CathWorks for up to $585 million.
- The deal adds non-invasive coronary artery disease diagnostic technology.
- Acquisition is expected to be completed by fiscal year 2026.
Medtronic announced its intention to purchase CathWorks, a privately held company, in a transaction valued up to $585 million. This strategic acquisition aims to bolster Medtronic's extensive portfolio of heart devices.
The deal will integrate the CathWorks FFRangio System, a cutting-edge non-invasive technology utilized for the diagnosis and assessment of coronary artery disease. This condition is a prevalent heart ailment characterized by plaque buildup restricting blood flow.
This move follows a partnership established between the two companies in 2022. The acquisition is subject to clearance from the U.S. Federal Trade Commission and is projected to finalize by the conclusion of Medtronic's fiscal year 2026.
